Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and vaccine markets.

A woman holds an anti-Elon Musk sign and an American flag in protest in front of the headquarters for United States Agency ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Q4 2024 Earnings Call Feb 04, 2025, 10:30 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street's revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer's future growth to ...

Pfizer Inc. (PFE) exceeded Wall Street expectations in its fourth-quarter and full-year 2024 earnings report, bolstered by ...

U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely ...

Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...